SCHEMBL20745993

SCHEMBL20745993

O=C1CCCCN1c1nccc(CO)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 3/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ATR Q13535 1/20 0.34
▸ ATRIP Q8WXE1 1/20 0.34
▸ HPGD P15428 3/20 0.34
▸ SORD Q00796 2/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ PIM1 P11309 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ MTOR P42345 2/20 0.32
▸ IDH1 O75874 1/20 0.32
▸ PIK3CA P42336 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24920541 0.78 RXRA (0.39) PARP1ALDH1A1L3MBTL1SMN1; SMN2HPGD
SCHEMBL20746423 0.77 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2ATRATRIPHPGD
SCHEMBL28059125 0.75 ACHE (0.46) SMN1; SMN2SORDMEN1KMT2ACYP3A4
SCHEMBL22320524 0.73 CRBN (0.50) PARP1ALDH1A1L3MBTL1SMN1; SMN2HPGD
SCHEMBL536720 0.71 PARP1 (0.57) PARP1ALDH1A1L3MBTL1HPGDPIM1
SCHEMBL16424985 0.70 PANK3 (0.39) PARP1ALDH1A1L3MBTL1NR1H2IDH1
SCHEMBL16815392 0.68 PIK3CA (0.51) SMN1; SMN2SORDMTORPIK3CAPIK3CB
SCHEMBL22262291 0.68 ACHE (0.52) ALDH1A1SORDNR1H2KMT2ACYP1A2
SCHEMBL8149641 0.67 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL20745038 0.67 PIK3CA (0.50) SMN1; SMN2SORDMTORPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112739343-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2021-04-30 — — CN disclosed
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-08-13 — — US disclosed
EP-3668504-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE AbbVie Inc. (US) 2020-06-24 — — EP disclosed
WO-2019035914-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC. (US) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 PARP1 247/4885ALDH1A1 647/4885L3MBTL1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback